What is the stock?

CSL is Australia’s leading biotechnology company. It is the global leader in the blood plasma therapies sector and the second-largest supplier of seasonal influenza vaccines, with combined annual sales of more than US$7.5 billion.

How long have you held the stock?

We have held it since June 2017.

To continue reading this article, take a free 21-day trial to the Switzer Report. Click here to sign up.